Tirzepatide is a synthetic peptide that activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP is another incretin hormone, released from K-cells in the upper small intestine, that historically was not considered a therapeutic target — but tirzepatide's clinical results forced a re-evaluation.
Why dual agonism matters
GIP appears to complement GLP-1 in several ways: it modulates insulin sensitivity in adipose tissue, influences energy expenditure signals, and may reduce some of the nausea associated with pure GLP-1 activation. Together, the two signals produce larger reductions in body weight and HbA1c than either alone in head-to-head trials.
Side-effect profile
The adverse-event profile is broadly similar to GLP-1 monotherapy: nausea, constipation, diarrhea, and reflux, most concentrated during dose escalation. Some clinical observations suggest slightly better GI tolerability at equivalent weight-loss efficacy compared with pure GLP-1 agents, but head-to-head comparisons are limited.
How to think about it
Tirzepatide is not a 'better semaglutide' in a vacuum. It is a different pharmacology with different dynamics. Which agent fits a particular person depends on medical history, prior tolerance, response, access, cost, and — critically — the lifestyle infrastructure around them.
“The medication is a lever. The bigger the lever, the more careful you have to be with the foundation underneath it. Bigger weight loss without protein and training is bigger muscle loss too.”
“I don't have a favorite molecule. I have a philosophy: whatever tool a client is using, the coaching wraps around the tool. On tirzepatide, appetite drops fast and food loses its emotional pull quickly. That is an opening — to lock in protein targets, to build a training rhythm that protects lean mass, to fix sleep. The medication buys you a window. The window closes eventually. What matters is what you built inside it.”
References
- Jastreboff AM, et al.. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. doi:10.1056/NEJMoa2206038
- Frías JP, et al.. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021. doi:10.1056/NEJMoa2107519
Related reading
8 min · Beginner
GLP-1 Fundamentals: How the Hormone Actually Works
GLP-1 is a naturally occurring gut hormone that quietly coordinates appetite, insulin release, and how quickly your stomach empties. Understanding it is the foundation for every conversation about modern metabolic therapies.
7 min · Beginner
Semaglutide: An Educational Overview
Semaglutide is the most widely studied GLP-1 receptor agonist. Understanding what it is, how it works, and where it fits changes how you use it.
7 min · Intermediate
Retatrutide: What the Triple Agonist Research Actually Shows
Retatrutide adds glucagon receptor agonism to the GLP-1/GIP combination. Early-phase data is striking — but it is still early-phase data, and context matters.
8 min · Intermediate
Muscle Preservation on GLP-1: Protecting Lean Mass While Losing Fat
Any rapid weight loss puts lean mass at risk. On GLP-1 therapy, the leverage points are protein and training — not the medication.
Apply this
Turn this education into a personalized plan.
Everything on this page is general education. The real leverage comes from applying it to your history, goals, and lifestyle. Start with our Health Assessment.